Updated research nosology for HIV-associated neurocognitive disorders.

HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology (2010) 12.32

HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol (2010) 7.56

Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology (2009) 4.07

HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis (2010) 3.46

Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study. Clin Infect Dis (2014) 3.09

Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neuropsychol Rev (2009) 2.86

CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS (2011) 2.31

Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology (2014) 2.18

Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology (2010) 2.17

Neurologic complications of HIV disease and their treatment. Top HIV Med (2010) 2.14

Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS (2011) 2.04

Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther (2010) 1.99

Timing is everything: antiretroviral nonadherence is associated with impairment in time-based prospective memory. J Int Neuropsychol Soc (2009) 1.94

The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res (2009) 1.93

Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS (2011) 1.90

Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J Immunol (2009) 1.85

Resting cerebral blood flow: a potential biomarker of the effects of HIV in the brain. Neurology (2009) 1.83

HIV-associated neurocognitive disorder - pathogenesis and prospects for treatment. Nat Rev Neurol (2016) 1.71

Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection. AIDS (2013) 1.71

HIV-1 Infection Accelerates Age According to the Epigenetic Clock. J Infect Dis (2015) 1.70

Incidence and nature of cognitive decline over 1 year among HIV-infected former plasma donors in China. AIDS (2010) 1.66

Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study. Neurology (2015) 1.66

Cognitive function in women with HIV: findings from the Women's Interagency HIV Study. Neurology (2014) 1.65

Neurobehavioral effects of human immunodeficiency virus infection among former plasma donors in rural China. J Neurovirol (2008) 1.64

Evaluating sleep and cognition in HIV. J Acquir Immune Defic Syndr (2013) 1.64

HIV subtype D is associated with dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda. Clin Infect Dis (2009) 1.64

Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV. Antivir Ther (2012) 1.64

A lipid storage-like disorder contributes to cognitive decline in HIV-infected subjects. Neurology (2013) 1.62

Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. AIDS (2012) 1.60

HIV-associated neurocognitive disorder. Lancet Infect Dis (2013) 1.60

Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol (2011) 1.57

White matter tract injury and cognitive impairment in human immunodeficiency virus-infected individuals. J Neurovirol (2009) 1.57

Antiretroviral therapy and central nervous system HIV type 1 infection. J Infect Dis (2008) 1.56

Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected people. Neurology (2014) 1.54

The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence? BMC Infect Dis (2011) 1.54

Diagnosing symptomatic HIV-associated neurocognitive disorders: self-report versus performance-based assessment of everyday functioning. J Int Neuropsychol Soc (2011) 1.53

Subcortical brain atrophy persists even in HAART-regulated HIV disease. Brain Imaging Behav (2011) 1.53

Plasma sCD14 is a biomarker associated with impaired neurocognitive test performance in attention and learning domains in HIV infection. J Acquir Immune Defic Syndr (2011) 1.52

Abnormalities in resting-state functional connectivity in early human immunodeficiency virus infection. Brain Connect (2011) 1.52

Co-morbidities in persons infected with HIV: increased burden with older age and negative effects on health-related quality of life. AIDS Patient Care STDS (2013) 1.51

MiR-21 in Extracellular Vesicles Leads to Neurotoxicity via TLR7 Signaling in SIV Neurological Disease. PLoS Pathog (2015) 1.50

A coat of many colors: neuroimmune crosstalk in human immunodeficiency virus infection. Neuron (2009) 1.48

Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder. Neurology (2012) 1.48

Medication and finance management among HIV-infected adults: the impact of age and cognition. J Clin Exp Neuropsychol (2010) 1.46

Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection. J Acquir Immune Defic Syndr (2012) 1.44

Neurocognitive Function and Neuroimaging Markers in Virologically Suppressed HIV-positive Patients Randomized to Ritonavir-boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-sectional Substudy From the PIVOT Trial. Clin Infect Dis (2016) 1.44

Antiretroviral neurotoxicity. J Neurovirol (2012) 1.43

Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Top Antivir Med (2011) 1.42

Macrophages and their relevance in Human Immunodeficiency Virus Type I infection. Retrovirology (2012) 1.41

HIV DNA and cognition in a Thai longitudinal HAART initiation cohort: the SEARCH 001 Cohort Study. Neurology (2009) 1.41

Molecular mechanisms of neuroinvasion by monocytes-macrophages in HIV-1 infection. Retrovirology (2010) 1.36

Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study. EBioMedicine (2015) 1.36

Lower brain glutamate is associated with cognitive deficits in HIV patients: a new mechanism for HIV-associated neurocognitive disorder. J Magn Reson Imaging (2010) 1.35

HIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment. Cold Spring Harb Perspect Med (2012) 1.34

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurol (2009) 1.32

HIV-1 neuroimmunity in the era of antiretroviral therapy. Neurobiol Dis (2010) 1.32

Neuropsychological assessment of HIV-infected populations in international settings. Neuropsychol Rev (2009) 1.31

Monocyte/macrophages and their role in HIV neuropathogenesis. Immunol Rev (2013) 1.31

HIV-associated neurocognitive disorders in sub-Saharan Africa: a pilot study in Cameroon. BMC Neurol (2010) 1.31

Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program. Clin Infect Dis (2012) 1.31

Screening for cognitive impairment in human immunodeficiency virus. Clin Infect Dis (2011) 1.30

Impact of apolipoprotein E ε4 and HIV on cognition and brain atrophy: antagonistic pleiotropy and premature brain aging. Neuroimage (2011) 1.29

Current understanding of HIV-associated neurocognitive disorders pathogenesis. Curr Opin Neurol (2011) 1.29

The National NeuroAIDS Tissue Consortium brain gene array: two types of HIV-associated neurocognitive impairment. PLoS One (2012) 1.27

Factors affecting brain structure in men with HIV disease in the post-HAART era. Neuroradiology (2011) 1.27

HIV DNA reservoir increases risk for cognitive disorders in cART-naïve patients. PLoS One (2013) 1.27

Declined neural efficiency in cognitively stable human immunodeficiency virus patients. Ann Neurol (2009) 1.26

Pathogenesis of HIV in the central nervous system. Curr HIV/AIDS Rep (2011) 1.26

Cognitive performance related to HIV-1-infected monocytes. J Neuropsychiatry Clin Neurosci (2012) 1.26

MicroRNA-21 dysregulates the expression of MEF2C in neurons in monkey and human SIV/HIV neurological disease. Cell Death Dis (2010) 1.26

HIV DNA in circulating monocytes as a mechanism to dementia and other HIV complications. J Leukoc Biol (2010) 1.24

Neuroimaging studies of the aging HIV-1-infected brain. J Neurovirol (2012) 1.23

Cerebral metabolite abnormalities in human immunodeficiency virus are associated with cortical and subcortical volumes. J Neurovirol (2010) 1.22

Monocyte maturation, HIV susceptibility, and transmigration across the blood brain barrier are critical in HIV neuropathogenesis. J Leukoc Biol (2012) 1.22

Loss of neuronal integrity during progressive HIV-1 infection of humanized mice. J Neurosci (2011) 1.22

Synergistic effects of HIV infection and older age on daily functioning. J Acquir Immune Defic Syndr (2012) 1.21

Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients. PLoS One (2014) 1.21

Depression, cognition, and self-appraisal of functional abilities in HIV: an examination of subjective appraisal versus objective performance. Clin Neuropsychol (2011) 1.21

Characterization of monocyte maturation/differentiation that facilitates their transmigration across the blood-brain barrier and infection by HIV: implications for NeuroAIDS. Cell Immunol (2010) 1.21

Neurovirological correlation with HIV-associated neurocognitive disorders and encephalitis in a HAART-era cohort. J Acquir Immune Defic Syndr (2013) 1.21

Neurocognitive impairment among HIV-positive individuals in Botswana: a pilot study. J Int AIDS Soc (2010) 1.20

Lower cognitive reserve among individuals with syndromic HIV-associated neurocognitive disorders (HAND). AIDS Behav (2012) 1.19

Drug abuse and hepatitis C infection as comorbid features of HIV associated neurocognitive disorder: neurocognitive and neuroimaging features. Neuropsychol Rev (2009) 1.17

Is it time to rethink how neuropsychological tests are used to diagnose mild forms of HIV-associated neurocognitive disorders? Impact of false-positive rates on prevalence and power. Neuroepidemiology (2013) 1.17

Neurocognitive impact of substance use in HIV infection. J Acquir Immune Defic Syndr (2011) 1.16

A concise panel of biomarkers identifies neurocognitive functioning changes in HIV-infected individuals. J Neuroimmune Pharmacol (2013) 1.15

Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy. J Infect Dis (2011) 1.15

Neuromodulatory activities of CD4+CD25+ regulatory T cells in a murine model of HIV-1-associated neurodegeneration. J Immunol (2009) 1.14

Significant effects of antiretroviral therapy on global gene expression in brain tissues of patients with HIV-1-associated neurocognitive disorders. PLoS Pathog (2011) 1.14

Prospective memory deficits are associated with unemployment in persons living with HIV infection. Rehabil Psychol (2011) 1.13

Human immunodeficiency virus type 1 infection increases the in vivo capacity of peripheral monocytes to cross the blood-brain barrier into the brain and the in vivo sensitivity of the blood-brain barrier to disruption by lipopolysaccharide. J Virol (2008) 1.13

Neurologic complications of HIV disease and their treatment. Top HIV Med (2009) 1.13

Neurologic presentations of AIDS. Neurol Clin (2010) 1.12

Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection. PLoS One (2014) 1.12

HIV-1 effects on neuropsychological performance in a resource-limited country, Zambia. AIDS Behav (2011) 1.12

Is prospective memory a dissociable cognitive function in HIV infection? J Clin Exp Neuropsychol (2010) 1.12

HIV-1 associated dementia: update on pathological mechanisms and therapeutic approaches. Curr Opin Neurol (2009) 1.12

Successful cognitive aging in persons living with HIV infection. J Neurovirol (2010) 1.11

Neurocognitive function in HIV infected patients on antiretroviral therapy. PLoS One (2013) 1.11

Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND Checklist. Pediatr Neurol (2014) 1.11

"Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res (1975) 301.74

Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA (1993) 12.83

The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc (2004) 6.64

UCSD Performance-Based Skills Assessment: development of a new measure of everyday functioning for severely mentally ill adults. Schizophr Bull (2001) 5.89

Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology (1991) 5.87

Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. J Clin Exp Neuropsychol (2004) 5.18

The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS (2005) 4.48

Distinguishing between overlapping somatic symptoms of depression and HIV disease in people living with HIV-AIDS. J Nerv Ment Dis (2000) 3.79

Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS (1999) 3.28

HIV Dementia Scale: a rapid screening test. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 3.17

A multimodal assessment of driving performance in HIV infection. Neurology (2004) 2.81

Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex. AIDS (2004) 2.72

Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS (2003) 2.69

Neurocognitive dysfunction predicts postmortem findings of HIV encephalitis. Neurology (2002) 2.47

Prevalence of human immunodeficiency virus-associated cognitive impairment in a group of Hispanic women at risk for neurological impairment. J Neurovirol (2006) 2.27

Medication management ability assessment: results from a performance-based measure in older outpatients with schizophrenia. J Clin Psychopharmacol (2002) 2.24

Neuropathologic confirmation of definitional criteria for human immunodeficiency virus-associated neurocognitive disorders. J Neurovirol (2007) 2.03

Motor analysis predicts progression in HIV-associated brain disease. J Neurol Sci (1994) 1.64

HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology (2010) 12.32

The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA (1998) 7.81

HTLV-III infection in brains of children and adults with AIDS encephalopathy. Science (1985) 7.70

Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med (2009) 7.53

Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet (1996) 7.10

The AIDS dementia complex: II. Neuropathology. Ann Neurol (1986) 5.61

Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication-competent and -defective viral genomes. J Virol (1991) 5.56

The HNRC 500--neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc (1995) 5.38

The AIDS dementia complex: I. Clinical features. Ann Neurol (1986) 5.22

Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo. J Virol (1992) 5.19

The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med (1994) 4.87

Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology (2011) 4.63

Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection. Lancet (1986) 4.54

Prevalence of serious eye disease and visual impairment in a north London population: population based, cross sectional study. BMJ (1998) 4.52

Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann Neurol (1997) 4.17

Acquired syphilis in adults. N Engl J Med (1992) 4.16

Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology (2009) 4.07

Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology (2010) 4.06

Phenomenology of prolonged febrile seizures: results of the FEBSTAT study. Neurology (2008) 3.83

Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann Neurol (1995) 3.78

The prevalence of dementia and Alzheimer's disease in Shanghai, China: impact of age, gender, and education. Ann Neurol (1990) 3.57

HIV-associated neurologic disease incidence changes:: Multicenter AIDS Cohort Study, 1990-1998. Neurology (2001) 3.55

Olfactory deficits in patients with mild cognitive impairment predict Alzheimer's disease at follow-up. Am J Psychiatry (2000) 3.54

Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology (1993) 3.53

Norms for letter and category fluency: demographic corrections for age, education, and ethnicity. Assessment (1999) 3.47

Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort. Neurology (2004) 3.44

Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center. Ann Neurol (1997) 3.38

Neuropsychological detection and characterization of preclinical Alzheimer's disease. Neurology (1995) 3.37

Cerebral toxoplasmosis complicating the acquired immune deficiency syndrome: clinical and neuropathological findings in 27 patients. Ann Neurol (1986) 3.33

Life quality of patients with chronic obstructive pulmonary disease. Arch Intern Med (1982) 3.30

Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS (1999) 3.28

Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA (1997) 3.17

HIV Dementia Scale: a rapid screening test. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 3.17

EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy. Eur J Neurol (2005) 3.17

Establishment of public health security in Saudi Arabia for the 2009 Hajj in response to pandemic influenza A H1N1. Lancet (2009) 3.15

Frequency of and risk factors for HIV dementia in an HIV clinic in sub-Saharan Africa. Neurology (2007) 3.14

CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology (2012) 3.12

Detecting significant change in neuropsychological test performance: a comparison of four models. J Int Neuropsychol Soc (1999) 3.11

Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol (2000) 3.01

The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988-1993. Am J Epidemiol (1995) 3.00

Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proc Natl Acad Sci U S A (1998) 2.89

Pilot association study of the beta-glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity. Mov Disord (2005) 2.88

Complete nucleotide sequence, genome organization, and biological properties of human immunodeficiency virus type 1 in vivo: evidence for limited defectiveness and complementation. J Virol (1992) 2.86

Human herpesvirus-6 infection in children. A prospective study of complications and reactivation. N Engl J Med (1994) 2.84

A multimodal assessment of driving performance in HIV infection. Neurology (2004) 2.81

Chronic neurological sequelae of acute organophosphate pesticide poisoning. Arch Environ Health (1988) 2.80

The AIDS dementia complex. J Infect Dis (1988) 2.77

Latent ganglionic infection with herpes simplex virus types 1 and 2: viral reactivation in vivo after neurectomy. Science (1974) 2.71

Changes in cognitive functioning following treatment of late-life depression. Am J Psychiatry (2000) 2.70

Vacuolar myelopathy pathologically resembling subacute combined degeneration in patients with the acquired immunodeficiency syndrome. N Engl J Med (1985) 2.70

Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. Ann Intern Med (1992) 2.65

Research evaluation and diagnosis of probable Alzheimer's disease over the last two decades: I. Neurology (2000) 2.64

Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet (1991) 2.60

Cytokine expression in the brain during the acquired immunodeficiency syndrome. Ann Neurol (1992) 2.52

Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology (1999) 2.52

HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology (1999) 2.49

The determination of low d5-phenylalanine enrichment (0.002-0.09 atom percent excess), after conversion to phenylethylamine, in relation to protein turnover studies by gas chromatography/electron ionization mass spectrometry. Rapid Commun Mass Spectrom (1992) 2.48

Test-retest reliability and practice effects of expanded Halstead-Reitan Neuropsychological Test Battery. J Int Neuropsychol Soc (1999) 2.47

Clinical-neuropathologic correlation in HIV-associated dementia. Neurology (1993) 2.47

Neuropathology of acquired immunodeficiency syndrome (AIDS): an autopsy review. J Neuropathol Exp Neurol (1986) 2.47

Neurocognitive dysfunction predicts postmortem findings of HIV encephalitis. Neurology (2002) 2.47

Generalized tensor-based morphometry of HIV/AIDS using multivariate statistics on deformation tensors. IEEE Trans Med Imaging (2008) 2.46

Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. Neurology (2005) 2.45

Physical activity predicts gray matter volume in late adulthood: the Cardiovascular Health Study. Neurology (2010) 2.41

Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology (2007) 2.41

Neuropsychological impairment in human immunodeficiency virus-infection: implications for employment. HNRC Group. HIV Neurobehavioral Research Center. Psychosom Med (1994) 2.39

Prevalence of psychiatric disorders among men infected with human immunodeficiency virus. A controlled study. Arch Gen Psychiatry (1988) 2.36

Detecting change: A comparison of three neuropsychological methods, using normal and clinical samples. Arch Clin Neuropsychol (2001) 2.35

Infection of chimpanzees by human T-lymphotropic retroviruses in brain and other tissues from AIDS patients. Lancet (1985) 2.35

Detection of HTLV-III RNA in lungs of patients with AIDS and pulmonary involvement. JAMA (1986) 2.30

HTLV-III/LAV-like retrovirus particles in the brains of patients with AIDS encephalopathy. AIDS Res (1986) 2.27

Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology (2012) 2.26

Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology (2006) 2.25

Pathologic features of AIDS encephalopathy in children: evidence for LAV/HTLV-III infection of brain. Hum Pathol (1986) 2.23

Localization of HIV-1 in human brain using polymerase chain reaction/in situ hybridization and immunocytochemistry. Ann Neurol (1996) 2.22

Demented and nondemented patients with AIDS differ in brain-derived human immunodeficiency virus type 1 envelope sequences. J Virol (1994) 2.21

Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology (2004) 2.18